Core Insights - The National Healthcare Security Administration (NHSA) is actively promoting the development of innovative drugs and medical devices in China, aligning with the directives from the 20th Central Committee of the Communist Party of China [1] Group 1: Policy Initiatives - NHSA is implementing dynamic adjustments to the medical insurance drug catalog to support the development of innovative drugs [1] - The establishment of a commercial insurance innovative drug catalog is part of the efforts to create a multi-faceted payment system for innovative drugs [1] - NHSA is conducting real-world comprehensive value assessments for medical insurance to better serve public health and enhance the high-quality development of the pharmaceutical industry [1] Group 2: Industry Engagement - NHSA encourages multinational companies to introduce advanced drugs, devices, and technologies into China [1] - The administration aims to integrate these innovations into the broader context of China's modernization efforts [1]